Hasil Pencarian  ::  Simpan CSV :: Kembali

Abstrak :
Latar belakang: Pandemi COVID-19 membawa perubahan yang besar terhadap sistem pelayanan kesehatan, salah satunya pada terapi kanker paru. Berbagai keterbatasan yang dihadapi tenaga kesehatan dan risiko COVID-19 yang tinggi pada pasien kanker paru menyebabkan terjadinya perubahan terapi pada pasien kanker paru. Penelitian ini bertujuan untuk mengetahui perubahan terapi dan tingkat kekhawatiran pada pasien kanker paru. Metode: Penelitian potong lintang yang melibatkan pasien rawat jalan kanker paru dilakukan di Poli Onkologi RSUP Persahabatan. Pemilihan sampel dilakukan menggunakan metode consecutive sampling. Perubahan terapi pasien kanker paru selama pandemi dinilai menggunakan survei daring yang disusun oleh Dutch Federation of Cancer Patients Organisations dan Dutch Multidisiplinary Oncology Foundation yang dimodifikasi dan diterjemahkan dalam Bahasa Indonesia. Karakteristik subjek yang meliputi karakteristik demografi, karakteristik kanker paru, jenis terapi, dan riwayat infeksi COVID-19 turut dinilai dalam penelitian ini. Hasil: Sebanyak 68,2% pasien kanker paru mengalami perubahan terapi selama pandemi COVID-19. Tidak ditemukan adanya korelasi antara karakteristik dan tingkat kekhawatiran subjek dengan perubahan terapi selama pandemi COVID-19. Kekhawatiran terhadap perubahan terapi ditemukan pada 77,3% subjek penelitian. Kesimpulan: Penelitian ini menemukan tingginya proporsi pasien kanker paru yang mengalami perubahan selama pandemi COVID-19. Perubahan terapi selama pandemi sebaiknya mempertimbangkan dampak psikologis pasien dan efektivitas terapi. Diperlukan penelitian lebih lanjut untuk mengetahui faktor-faktor yang memengaruhi perubahan terapi selama pandemi COVID-19. ......Introduction: The COVID-19 pandemic has brought major changes to the health care system, one of which is lung cancer treatment. Various limitations faced by health workers and the high risk of COVID-19 in lung cancer patients led to changes in lung cancer treatment. This study aims to assess changes in therapy and level of concern in lung cancer patients. Method: A cross-sectional study involving lung cancer outpatients was conducted in Thoracic Oncology Outpatient Clinic in Persahabatan National Respiratory Referral Hospital Jakarta, Indonesia. Sample recruitment was done using consecutive sampling method. Changes in therapy for lung cancer patients during the pandemic were assessed using an online survey by the Dutch Federation of Cancer Patients Organizations and the Dutch Multidisciplinary Oncology Foundation which was modified and translated into Bahasa. Patients characteristics, including demographic characteristics, lung cancer characteristics, type of therapy, and history of COVID-19 infection were also assessed in this study. Result: A total of 68.2% of lung cancer patients reported changes in therapy during the COVID-19 pandemic and 77,3% were concerned about treatment changes. No correlation was found between the characteristics and level of concern of the subjects with changes in treatment during the COVID-19 pandemic. Conclusion: This study found a high proportion of lung cancer patients who experienced changes during the COVID-19 pandemic. Changes in therapy during a pandemic should take into account the psychological impact of the patient and the effectiveness of therapy. Further research is needed to determine the factors that influence the changes during the COVID-19 pandemic.

Abstrak :
Tujuan: Mengetahui aktivitas MnSOD pada darah penderita kanker paru dengan riwayat merokok, menilai hubungan aktivitas MnSOD dengan stres oksidatif dan genotipe MnSOD. Metode: Penelitian ini adalah studi kasus kontrol. Sampel yang digunakan adalah set leukosit dari 20 pasien kanker paru di RS Persahahatao Jakarta, Kontrol adalah 50 pcrokok dan 50 non perokok dari pabrik pulp di Tangerang. Pcmeriksaan aktivitas spesifik MnSOD berdasarkan prinsip penghambatan terhadap xantin oxidase. untuk menghambat Cu/ZnSOD perlu ditambahkan natrium sianida 5 mM pada sampel lalu diinkubnsi 5 menit pada suhu ruang. Kadar MDA plasma ditcntukan berdasarkan reaksi dcngan asam tiobarbituat membentuk produk berwama merah sesuai metod: Wills, pengukuran kadar karbonil plasma menggunakan metode modifikasi Levine. Aktivitas spesifik katalnse ditentukan berdasarkan penguraian H2O2 yang terjadi menglkuti metode modiflkasi Mates. Pemeriksaan genotype menggunakan metode PCR-RFLP dengan NgoMIV sebagai enzim restriksi. Hasil: Kadar MDA plasma pada paslen kanker paru kbih rcndah cJibundingk0-n konlrol (p*"0,479). Hal ini merupakan konsekuensi dari progresivitas tumor mekanisme yang menyebabkan belum jelas). mekanisme adaptasi terhadap stres oksidatif atau digunakan sebagai sumber pcmbentukan oksidasi protein. Kadar karbonil plasma pada pasien kanker paru lebih tinggi dibandingkan konfrol (p=0.003), Hal ini menandakan sistem antloksidan telah jenuh dengan ROS yang tinggi dl jaringan paru, juga menandakan kerusakan sel yang lebih luas dan berat. Aktivitas spesifik katalase pada darah penderita kanker paru lebih rendah daripada ke!ompok kontrol (p=0.036). Hal ini mungkin disebabkan oleh ROS di jaringan yang tinggi atau karcna telah terjadi kerusakan oksidatif pada protein. Aktivitas spesifik MnSOD pada pusien kanker paru lebih rendah datipada kontrol (p=0,000). Hal ini menunjukkan enzim MnSOD telah jenuh oleh ROS yang banyak, kerusakan oksidatif pada protein MnSOD. atau gangguan transpor MnSOD, Aktivitas spesifik MnSOD pada perokok juga lebih rendah dilbandingkan dengan non perokok, Hal ini menunjukkan bahwa pajanan asap rokok yang kontinu mcningkatkan pruduksi ROS sehingga aktivitas enzim menurun. Studi ini menemukan genotipe Val/val dan Val/Ala pada kelompok kanker paru (80% dan 20%), pada perokok (90% dan 10%), dan non perokok (100% dan 0%). Kami tidak menemukan genotipe Ala/Ala pada kelompok kasus dan kontrol. Tidak terdapat hubungan yang bermakna antara genotipe dengan aktivitas spesifik MnSOD. Kesimpulan: Kebiasaan metokok mempengaruhi aktivitas spesifik MnSOD di darah. Penyakin kanker paru dengan kebiasaan merokok mempengaruhi aktivitas spesifik MnSOD di darah. Perubahan aktivitas spesifik MnSOD berkorelasi lemah dengan kerusakan oksidatif baik pada kelompok kanker paru, kontrol perokok, dan non perokok. Tidak ada hubungan yang bermakna antara aktivitas spesifik MnSOD dengan genotipe MnSOD Ala16Val pada kekompok kanker paru dan kontrol. Aktivitas spesifik MnSOD dalam darah dapat diusulkan sebagai petanda dini karsinogenesis paru pada perokok.

Abstrak :
Latar belakang : Toksisitas hematologi sering terjadi pada pasien dengan Kanker Paru Karsinoma Bukan Sel Kecil (KPKBSK) yang diobati dengan kemoterapi berbasis platinum. Data sebelumnya menunjukkan bahwa trombositopenia karena kemoterapi berbasis karboplatin adalah rendah tetapi tidak ada data lokal yang menjelaskan angka kejadian trombositopenia pada KPKBSK yang diterapi dengan regimen karboplatin+gemsitabin. Tujuan dari penelitian ini adalah untuk melihat dan membandingkan angka kejadian toksisitas hematologi seperti trombositopenia, anemia, leucopenia, neutropenia dan perdarahan yang disebabkan kemoterapi karboplatin+gemsitabin dengan karboplatin+paklitaksel dan karboplatin+etoposid pada pasien KPKBSK. Dan juga membandingkan respons objektif dari ketiga regimen tersebut. Metode:. Penelitian ini kohort retrospektif pada pada pasien KPKBSK yang menerima 1.250 mg/m2 gemsitabin pada hari ke-1 dan hari ke-8 dan karboplatin AUC-5(Area under curve) hari pertama. Pasien yang menerima ≥ 2 siklus ikut dalam penelitian ini. Kami menilai dan membandingkan toksisitas hematologi tiap siklus seperti trombositopenia, anemia, leucopenia, neutropenia dan perdarahan serta respons objektif dari ketiga regimen berbasis karboplatin selama kemoterapi. Hasil: Pada penelitian ini didapatkan total 115 pasien (rerata umur 55.6±10, rerata jumlah siklus adalah 4, jenis histologi adenokarsinoma 91%, stage III or IV) Pasien KPKBSK yang menerima regimen karboplatin+gemsitabine (n=38), karboplatin+paklitaksel (n=39) dan karboplatin+etoposid (n=38). Angka kejadian trombositopenia regimen karboplatin+gemsitabin adalah 34.2%, karboplatin+paklitaksel 5.1%, dan karboplatin+etoposid 5.3%. Waktu terjadinya trrombositopenia pada regimen karboplatin+gemsitabin 2 siklus lebih cepat dari regimen lain. Toksisiti hematologi trombositopenia regimen karboplatin+gemsitabin sebesar 15,8% dengan grade 3-4, leukopenia 18,4% dengan grade 3- 4 dan anemia 5,3% grade 3-4. Overall respons rate dan time to progression dengan regimen karboplatin+gemsitabin lebih baik dari regimen lainnya. Kesimpulan : Angka kejadian dan waktu terjadinya toksisitas hematologi pada regimen karboplatin+gemsitabin lebih tinggi daripada regimen karboplatin+paklitaksel dan karboplatin+etoposid.. Tetapi Overall respons rate dan time to progression pada karboplatin+gemsitabin lebih baik daripada regimen lain. Background : Hematological toxicities often occur in patients with non-small-cell lung cancer (NSCLC) who are treated with chemotherapy. In our data had shown that thrombocytopenia due to carboplatin based chemotherapy was low but there was not any local data about carboplatin - gemcitabine regimen. The aim of this study is to investigate and to compare the frequency of hematologic events, such as thrombocytopenia, anemia, leucopenia, neutropenia, and hemorrhage due to combination of gemcitabine-carboplatin with carboplatin-paclitaxel, and carboplatin-etoposide in non-small cell lung cancer patients. And also to compare objective response of the three platinum based regimens. Methods : We conducted a retrospective cohort study that enrolled all non-small-cell lung cancer patients who received 1.250 mg/m2 gemcitabine on day 1,8 and AUC-5 carboplatin on day one. Patients who received 2 cycles or more are included in this study. We investigated and compared objective response of the three platinum based regimens and the frequency of thrombocytopenia, anemia, leucopenia, neutropenia, hemorrhage, during chemotherapy period. Results : A total 115 patients (mean age 55.6±10, median number of cycle of chemotherapy was 4, histological findings were adenocarcinoma 91%) with stage III or IV NSCLC received chemotherapy carboplatin-gemcitabine (n=38), carboplatin-paclitaxel (n=39) and carboplatin-etoposide (n=38). Frequency of thrombocytopenia in patients with NSCLC treated with combination of carboplatin-gemcitabin regimen was 34.2%, carboplatin-paclitaxel 5.1%, and carboplatin-etoposide 5.3%. The Carbo-gemcitabine group developed thrombocytopenia 1 or 2 cycles earlier than other group . The hematological toxicities data with carbo-gemcitabine regimen have shown that thrombocytopenia was 15,8% patient with grade 3 or 4, leucopenia 18,4% patients with grade 3 or 4 and 5,3% grade 3 or 4 anemia. Overall respons rate and time to progression with carboplatin-gemcitabine regimen were better than the other regimens Conclusion : Thrombocytopenia was found in gemcitabine and carboplatin regimen but lower than other published data. Overall respons rate and time to progression with carboplatin-gemcitabine regimen were better than the other regimens.

Abstrak :
[ABSTRAK
Pendahuluan. Kanker paru jenis karsinoma bukan sel kecil (KPKBSK) terdiri dari nonskuamosa dan skuamosa. Kanker paru jenis karsinoma bukan sel kecil nonskuamosa adalah adenokarsinoma dan karsinoma sel besar. Saat ini terapi kanker paru sangat berkembang dari agen kemoterapi sampai terapi target terutama EGFR-TKI. Penelitian ini bertujuan untuk menilai angka tahan hidup pasien KPKSBK nonskuamosa yang mendapat kemoterapi lini pertama dibandingkan terapi EGFR-TKI di RSUP Persahabatan. Metode. Penelitian ini adalah penelitian retrospektif antara tahun 2010 sampai 2013 dari rekam medis pasien KPKBSK non skumosa yang mendapatkan kemoterapi lini pertama dan EGFR-TKI. Pasien dikemoterapi dengan platinum baseddan EGFR-TKI diterapi gefitinib 1x250 mg/hari atau erlotinib 1x150 mg/hari. Angka tahan hidup dinilai dari mulai tegak diagnosis sampai pasien meninggal atau saat penelitian dihentikan. Hasil. Dari 96 sampel KPKBSK non skuamosa terdiri dari 48 pasien yang mendapat kemoterapi lini pertama dan 48 pasien yang diterapi EGFR-TKI. Berdasarkan karakteristik pasien, usia terbanyak adalah 40-60 tahun (kemoterapi 32 (66,7%) dan EGFR-TKI 31 (64,6%) dengan jenis kelamin laki-laki yang mendominasi (kemoterapi 25(52,1%), EGFR-TKI 27 (56,2%). Pasien merokok yang mendapat kemoterapi lini pertama 41,7% dan EGFR-TKI 56,3% dengan IB terbanyak untuk kemoterapi (IB ringan 27,1%) dan untuk EGFR-TKI (IB sedang 22,9%). Jenis histologi adenokarsinoma 95,8% dengan dominasi stage IV 89,6% (kemoterapi 91,7% dan EGFR-TKI 87,5%) disertai tampilan status 2 59,4%. Angka tahan hidup pasien (ATH) 6 bulan 74%, ATH 1 tahun 22,90% dan ATH 2 tahun 6,20%. Masa tengah tahan hidup (MTTH) pasien yang mendapat EGFR-TKI lebih lama sedikit dibandingkan yang mendapat kemoterapi lini pertama (263 hari versus 260 hari. Kesimpulan. Masa tahan hidup 1 tahun pasien KPKBSK non skuamosa yang diterapi EGFR-TKI sedikit lebih lama dibandingkan kemoterapi lini pertama (263 hari vs 260 hari). Sedangkan ATH 1 tahun pasien kemoterapi lini pertama lebih besar dibandingkan EGFR-TKI (25% vs 20,8%). Faktor yang paling mempengaruhi angka tahan hidup adalah stage dengan nilai p<0,05.

---

ABSTRACT
Introduction. Lung cancer is the type of non-small cell carcinoma (NSCLC) consists of non-squamous and squamous. Non-small cell lung cancer of non squamous types consist of adenocarcinoma and large cell carcinoma. Currently, lung cancer therapy is highly developed of chemotherapeutic agents to targeted therapy especially EGFR-TKI. This study aims to assess the survival rate of NSCLC patients of non-squamous type who receive first line chemotherapy and those who recieve EGFR-TKI therapy at Persahabatan hospital. Methods. This study is a retrospective study between 2010 to 2013 from the medical records of NSCLC patients of non-squmous type who receive first-line chemotherapy and thise who recieve EGFR-TKI.Patients with platinum-based chemotherapy and EGFR-TKI with gefitinib therapy 1x250 mg/day or erlotinib 1x150mg/day. Survival rate assessed from start to erect the diagnosis until the patient dies or when the study is discontinued. Result. From 96 subject of NSCLC patients with non-squamous type consisted of 48 patients who receive first-line chemotherapy, and 48 patients are treate with EGFR-TKI. Based on the characteristics of the patients, most are 40-60 years old (chemotherapy 32 (66.7%) and EGFR-TKI 31 (64.6%) with the male gender that dominates (chemotherapy 25 (52.1%), EGFR-TKI 27 (56.2%). Smoking patients who received first-line chemotherapy are 41.7% and 56.3% of EGFR-TKIs with chemotherapy highest IB (mild IB 27.1%) and for EGFR-TKI (moderate IB are 22.9%). 95.8% of adenocarcinoma histology type with a predominance of stage IV 89.6% (91.7% for chemotherapy and EGFR-TKI 87.5%) with performance status 2 59.4% . Survival rate of patients are 74% for 6 months survival, 1 year survival rate is 22.90% and 2 years survival rate of 6.20%. Median period of survival rate in patients who receiving EGFR-TKI longer than they received first-line chemotherapy (263 days versus 260 days). Conclusion. Median survival rate of non-squamous NSCLC that treated by EGFR-TKI is longer than first-line chemotherapy (263 days vs 260 days). Although 1 year survival rate first-line chemotherapy in patients is greater than EGFR-TKI (25% vs 20.8%). The factors that most influence the survival rate is stages with p value<0.05.;Introduction. Lung cancer is the type of non-small cell carcinoma (NSCLC) consists of non-squamous and squamous. Non-small cell lung cancer of non squamous types consist of adenocarcinoma and large cell carcinoma. Currently, lung cancer therapy is highly developed of chemotherapeutic agents to targeted therapy especially EGFR-TKI. This study aims to assess the survival rate of NSCLC patients of non-squamous type who receive first line chemotherapy and those who recieve EGFR-TKI therapy at Persahabatan hospital. Methods. This study is a retrospective study between 2010 to 2013 from the medical records of NSCLC patients of non-squmous type who receive first-line chemotherapy and thise who recieve EGFR-TKI.Patients with platinum-based chemotherapy and EGFR-TKI with gefitinib therapy 1x250 mg/day or erlotinib 1x150mg/day. Survival rate assessed from start to erect the diagnosis until the patient dies or when the study is discontinued. Result. From 96 subject of NSCLC patients with non-squamous type consisted of 48 patients who receive first-line chemotherapy, and 48 patients are treate with EGFR-TKI. Based on the characteristics of the patients, most are 40-60 years old (chemotherapy 32 (66.7%) and EGFR-TKI 31 (64.6%) with the male gender that dominates (chemotherapy 25 (52.1%), EGFR-TKI 27 (56.2%). Smoking patients who received first-line chemotherapy are 41.7% and 56.3% of EGFR-TKIs with chemotherapy highest IB (mild IB 27.1%) and for EGFR-TKI (moderate IB are 22.9%). 95.8% of adenocarcinoma histology type with a predominance of stage IV 89.6% (91.7% for chemotherapy and EGFR-TKI 87.5%) with performance status 2 59.4% . Survival rate of patients are 74% for 6 months survival, 1 year survival rate is 22.90% and 2 years survival rate of 6.20%. Median period of survival rate in patients who receiving EGFR-TKI longer than they received first-line chemotherapy (263 days versus 260 days). Conclusion. Median survival rate of non-squamous NSCLC that treated by EGFR-TKI is longer than first-line chemotherapy (263 days vs 260 days). Although 1 year survival rate first-line chemotherapy in patients is greater than EGFR-TKI (25% vs 20.8%). The factors that most influence the survival rate is stages with p value<0.05.;Introduction. Lung cancer is the type of non-small cell carcinoma (NSCLC) consists of non-squamous and squamous. Non-small cell lung cancer of non squamous types consist of adenocarcinoma and large cell carcinoma. Currently, lung cancer therapy is highly developed of chemotherapeutic agents to targeted therapy especially EGFR-TKI. This study aims to assess the survival rate of NSCLC patients of non-squamous type who receive first line chemotherapy and those who recieve EGFR-TKI therapy at Persahabatan hospital. Methods. This study is a retrospective study between 2010 to 2013 from the medical records of NSCLC patients of non-squmous type who receive first-line chemotherapy and thise who recieve EGFR-TKI.Patients with platinum-based chemotherapy and EGFR-TKI with gefitinib therapy 1x250 mg/day or erlotinib 1x150mg/day. Survival rate assessed from start to erect the diagnosis until the patient dies or when the study is discontinued. Result. From 96 subject of NSCLC patients with non-squamous type consisted of 48 patients who receive first-line chemotherapy, and 48 patients are treate with EGFR-TKI. Based on the characteristics of the patients, most are 40-60 years old (chemotherapy 32 (66.7%) and EGFR-TKI 31 (64.6%) with the male gender that dominates (chemotherapy 25 (52.1%), EGFR-TKI 27 (56.2%). Smoking patients who received first-line chemotherapy are 41.7% and 56.3% of EGFR-TKIs with chemotherapy highest IB (mild IB 27.1%) and for EGFR-TKI (moderate IB are 22.9%). 95.8% of adenocarcinoma histology type with a predominance of stage IV 89.6% (91.7% for chemotherapy and EGFR-TKI 87.5%) with performance status 2 59.4% . Survival rate of patients are 74% for 6 months survival, 1 year survival rate is 22.90% and 2 years survival rate of 6.20%. Median period of survival rate in patients who receiving EGFR-TKI longer than they received first-line chemotherapy (263 days versus 260 days). Conclusion. Median survival rate of non-squamous NSCLC that treated by EGFR-TKI is longer than first-line chemotherapy (263 days vs 260 days). Although 1 year survival rate first-line chemotherapy in patients is greater than EGFR-TKI (25% vs 20.8%). The factors that most influence the survival rate is stages with p value<0.05.;Introduction. Lung cancer is the type of non-small cell carcinoma (NSCLC) consists of non-squamous and squamous. Non-small cell lung cancer of non squamous types consist of adenocarcinoma and large cell carcinoma. Currently, lung cancer therapy is highly developed of chemotherapeutic agents to targeted therapy especially EGFR-TKI. This study aims to assess the survival rate of NSCLC patients of non-squamous type who receive first line chemotherapy and those who recieve EGFR-TKI therapy at Persahabatan hospital. Methods. This study is a retrospective study between 2010 to 2013 from the medical records of NSCLC patients of non-squmous type who receive first-line chemotherapy and thise who recieve EGFR-TKI.Patients with platinum-based chemotherapy and EGFR-TKI with gefitinib therapy 1x250 mg/day or erlotinib 1x150mg/day. Survival rate assessed from start to erect the diagnosis until the patient dies or when the study is discontinued. Result. From 96 subject of NSCLC patients with non-squamous type consisted of 48 patients who receive first-line chemotherapy, and 48 patients are treate with EGFR-TKI. Based on the characteristics of the patients, most are 40-60 years old (chemotherapy 32 (66.7%) and EGFR-TKI 31 (64.6%) with the male gender that dominates (chemotherapy 25 (52.1%), EGFR-TKI 27 (56.2%). Smoking patients who received first-line chemotherapy are 41.7% and 56.3% of EGFR-TKIs with chemotherapy highest IB (mild IB 27.1%) and for EGFR-TKI (moderate IB are 22.9%). 95.8% of adenocarcinoma histology type with a predominance of stage IV 89.6% (91.7% for chemotherapy and EGFR-TKI 87.5%) with performance status 2 59.4% . Survival rate of patients are 74% for 6 months survival, 1 year survival rate is 22.90% and 2 years survival rate of 6.20%. Median period of survival rate in patients who receiving EGFR-TKI longer than they received first-line chemotherapy (263 days versus 260 days). Conclusion. Median survival rate of non-squamous NSCLC that treated by EGFR-TKI is longer than first-line chemotherapy (263 days vs 260 days). Although 1 year survival rate first-line chemotherapy in patients is greater than EGFR-TKI (25% vs 20.8%). The factors that most influence the survival rate is stages with p value<0.05., Introduction. Lung cancer is the type of non-small cell carcinoma (NSCLC) consists of non-squamous and squamous. Non-small cell lung cancer of non squamous types consist of adenocarcinoma and large cell carcinoma. Currently, lung cancer therapy is highly developed of chemotherapeutic agents to targeted therapy especially EGFR-TKI. This study aims to assess the survival rate of NSCLC patients of non-squamous type who receive first line chemotherapy and those who recieve EGFR-TKI therapy at Persahabatan hospital. Methods. This study is a retrospective study between 2010 to 2013 from the medical records of NSCLC patients of non-squmous type who receive first-line chemotherapy and thise who recieve EGFR-TKI.Patients with platinum-based chemotherapy and EGFR-TKI with gefitinib therapy 1x250 mg/day or erlotinib 1x150mg/day. Survival rate assessed from start to erect the diagnosis until the patient dies or when the study is discontinued. Result. From 96 subject of NSCLC patients with non-squamous type consisted of 48 patients who receive first-line chemotherapy, and 48 patients are treate with EGFR-TKI. Based on the characteristics of the patients, most are 40-60 years old (chemotherapy 32 (66.7%) and EGFR-TKI 31 (64.6%) with the male gender that dominates (chemotherapy 25 (52.1%), EGFR-TKI 27 (56.2%). Smoking patients who received first-line chemotherapy are 41.7% and 56.3% of EGFR-TKIs with chemotherapy highest IB (mild IB 27.1%) and for EGFR-TKI (moderate IB are 22.9%). 95.8% of adenocarcinoma histology type with a predominance of stage IV 89.6% (91.7% for chemotherapy and EGFR-TKI 87.5%) with performance status 2 59.4% . Survival rate of patients are 74% for 6 months survival, 1 year survival rate is 22.90% and 2 years survival rate of 6.20%. Median period of survival rate in patients who receiving EGFR-TKI longer than they received first-line chemotherapy (263 days versus 260 days). Conclusion. Median survival rate of non-squamous NSCLC that treated by EGFR-TKI is longer than first-line chemotherapy (263 days vs 260 days). Although 1 year survival rate first-line chemotherapy in patients is greater than EGFR-TKI (25% vs 20.8%). The factors that most influence the survival rate is stages with p value<0.05.]

Abstrak :
Salah satu cara untuk mengeloinpokkan ketahanan pasien penyakit kanker paru yang menjalani perlakuan reseksi, kemoterapi dan radioterapi adalah teknik analisis diskriminan linier. Analisis ini menggunakan fungsi diskriminan linier yang dibentuk berdasarkan beberapa variabel berdasarkan karakteristik individu pasien atau disebut juga faktor resiko yang mempengaruhi ketahanan pasien. Prosedur analisis ini dapat dirinci sebagai berikut: 1. Menemukan faktor-faktor resiko yang penting, yaitu yang memberikan konstribusi pada fungsi diskriminan linier. 2. Menentukan fungsi diskrirninan linier yang efisien dengan menggunakan variabel-variabel atau faktor-faktor resiko untuk pengelompokan ketahanan suatu individu. Data yang dipakai adalah data retrospektif pasien Ruinah Sakit Persahabatan tahun 1978-1990. Sebagai temuan didapat fungsi diskriminan yang mengandung faktor umur, jenis kelamin dan faktor-faktor yang bersangkutan dengan jenis sel, stadium dan masing-masing perlakuan.

Abstrak :
Kanker paru adalah semua penyakit keganasan di paru baik yang berasal dari paru sendiri maupun keganasan dari luar paru Penelitian ini bertujuan untuk mengetahui faktor risiko kejadian kanker paru pada pasien rawat inap dan rawat jalan di RSUPN Dr Cipto Mangunkusumo Jakarta RSCM Tahun 2011 2012 Desain penelitian ini adalah kasus kontrol dan dianalisis secara univariat dan bivariat Sampel dalam penelitian ini adalah pasien yang menjalani pelayanan rawat inap dan rawat jalan di bagian pulmonologi RSCM dan memiliki catatan rekam medis yang lengkap Hasil penelitian menunjukkan bahwa pasien laki laki memiliki risiko 2 05 95 CI 1 062 3 974 kali lebih besar untuk terkena kanker paru dibandingkan pasien perempuan Kemudian untuk tingkat pendidikan rendah memiliki risiko 0 23 95 CI 0 08 0 64 kali lebih besar untuk terkena kanker paru dibandingkan pasien dengan tingkat pendidikan tinggi Hasil penelitian juga menunjukkan bahwa pasien yang merokok memiliki risiko 3 19 95 CI 1 63 2 23 kali lebih besar untuk terkena kanker paru dibandingkan pasien yang tidak merokok pasien yang merokok ge 20 batang per hari memiliki risiko 7 62 95 CI 2 00 28 97 kali lebih besar dibandingkan pasien yang tidak merokok dan pasien yang merokok selama 1 24 tahun memiliki risiko 3 87 95 CI 1 89 7 91 kali lebih besar dibandingkan pasien yang tidak merokok. ...... Lung cancer is all of malignant lung disease including malignancy derived from the lung itself or from extrapulmonary malignancy This study aims to determine the risk factors of lung cancer incidence in Inpatient and Outpatient at Dr Cipto Mangunkusumo Hospital RSCM in Jakarta 2011 2012 This study design is case control with univariate and bivariate analyzes The samples in this study were patients undergoing inpatient and outpatient at pulmonologi RSCM and have a complete medical record Results showed that male patients had a risk of 2 05 95 CI 1 062 to 3 974 times greater for lung cancer than women For the low education levels have an increased risk of 0 23 95 CI 0 08 0 64 times greater for lung cancer than patients with higher education levels The results also showed that patients who smoke have a risk of 3 19 95 CI 1 63 to 2 23 times greater for lung cancer than non smokers patients who smoked ge 20 cigarettes per day had a risk of 7 62 95 CI 2 00 to 28 97 times greater than patients who did not smoke and patients who smoked for 1 24 years had a risk of 3 87 95 CI 1 89 to 7 91 times greater than patients who do not smoke.

Abstrak :
Latar belakang: Situasi pandemi COVID-19 membawa dampak terhadap berbagai aspek kehidupan, terutama pada masyarakat dengan penyakit kronis seperti kanker paru. Perubahan akibat pandemi memengaruhi tingkat kualitas hidup pasien yang penting untuk kesejahteraan hidup mereka. Penelitian ini bertujuan untuk memberikan gambaran kualitas hidup pasien kanker paru pada pandemi COVID-19. Metode: Studi dengan metode potong-lintang dilakukan di Poli Rawat Jalan Onkologi Toraks RSUP Persahabatan, Jakarta. Sampel diambil menggunakan metode consecutive sampling. Tingkat kualitas hidup dinilai menggunakan kuesioner European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items (EORTC QLQ-C30) versi Bahasa Indonesia. Penelitian ini juga menilai karakteristik sosiodemografis dan klinis pasien, serta faktor terkait COVID-19 yang meliputi kekhawatiran akan terhambatnya pengobatan, paparan informasi mengenai COVID-19, hambatan akses menuju fasilitas kesehatan, hambatan kelanjutan pengobatan, tekanan mental yang dialami, serta hubungan dengan keluarga dan teman selama pandemi COVID-19. Hasil: Sebanyak 94% dan 6% pasien kanker paru memiliki tingkat kualitas hidup sedang dan buruk selama pandemi COVID-19. Keseluruhan pasien mengalami gangguan kualitas hidup selama pandemi, tetapi tidak ditemukan adanya hubungan yang bermakna secara statistik pada tingkat kualitas hidup dengan karakteristik subjek, maupun dengan pandemi COVID-19. Sebagian besar pasien mengkhawatirkan keterlambatan pengobatan dan mengalami tekanan psikologis, namun hanya sedikit pasien yang mengalami hambatan pengobatan selama pandemi. Kesimpulan: Studi ini menunjukkan adanya gangguan kualitas hidup pada pasien kanker paru selama pandemi COVID-19. Diperlukan adanya penelitian lebih lanjut serta pengembangan intervensi yang lebih holistik dan komprehensif untuk pasien kanker paru, terutama selama pengobatan jarak jauh. Kata kunci: Kanker Paru, Kualitas Hidup, COVID-19 ......Introduction: The COVID-19 pandemic has affected various aspects of life, especially for people with chronic diseases such as lung cancer. The changes due to the pandemic impact their quality of life (QoL) which is important for their well-being. This study aimed to provide an overview of lung cancer patients’ QoL during the COVID-19 pandemic. Method: A cross-sectional study was conducted in the Thoracic Oncology Outpatient Clinic of Persahabatan National Respiratory Referral Hospital, Jakarta. Patients were recruited using consecutive sampling methods. QoL was assessed using the Indonesian version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items (EORTC QLQ-C30). This study also assessed the patients’ sociodemographic and clinical characteristics and the factors related to COVID-19, including concerns about treatment delays, exposure to COVID-19 information, barriers to access to healthcare facilities and treatment continuation, psychological pressure, and interpersonal relationships with family and friends. Results: 94% and 6% of lung cancer patients have moderate and poor QoL during the COVID-19 pandemic. All patients have impaired QoL, but no statistically significant relationship was found between QoL and the subjects’ characteristics or the factors related to the pandemic. Most patients are concerned about treatment delays and experiencing psychological pressure, but only a few patients experience treatment barriers during the pandemic. Conclusion: This study showed an impaired QoL in lung cancer patients during the COVID-19 pandemic. Further research and development of more holistic and comprehensive interventions for lung cancer patients, particularly during remote treatment, are needed.